Borealis Biosciences, Inc. is focused on developing RNA medicines specifically aimed at treating kidney diseases, which represent a significant global health challenge. The company leverages advancements in RNA therapeutics to address the unmet medical needs of patients suffering from chronic kidney diseases, which affect approximately 1 in 7 individuals worldwide. Borealis builds on the foundational work of Chinook Therapeutics, emphasizing the importance of targeted delivery of RNA therapeutics and the integration of translational systems biology and data sciences. This approach aims to improve treatment outcomes for kidney diseases that have historically lacked effective therapies, particularly for conditions like IgA nephropathy.

The company’s innovative strategies are rooted in a deep understanding of the distinct subpopulations of kidney disease patients and their underlying pathologies. Borealis believes that traditional small molecule or biologic treatments may not adequately address some of the most validated causal targets in kidney disease. By focusing on directing RNA specifically to kidney cells, Borealis aims to transform the treatment landscape for these conditions, potentially leading to more effective therapies that can significantly enhance patient quality of life.

Canada

Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.

Borealis Biosciences, Inc.

Company Details